{
    "organizations": [],
    "uuid": "395ad53c23ab17fc98b6527f6c831c10654cf224",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-expres2ion-rights-issue-oversubscr/brief-expres2ion-rights-issue-oversubscribed-idUSASM000JZP",
    "ord_in_thread": 0,
    "title": "BRIEF-ExpreS2ion Rights Issue Oversubscribed",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 2 (Reuters) - EXPRES2ION BIOTECH HOLDING AB :\n* PRESS RELEASE - EXPRES2ION’S RIGHTS ISSUE OVERSUBSCRIBED\n* ‍RIGHTS ISSUE OF APPROXIMATELY SEK 19.2 MILLION HAS BEEN OVERSUBSCRIBED​\n* ‍RIGHTS ISSUE WAS SUBSCRIBED TO APPROXIMATELY SEK 30.3 MILLION\n* ‍RIGHTS ISSUE WAS SUBSCRIBED TO APPROXIMATELY SEK 30.3 MILLION, CORRESPONDING TO A SUBSCRIPTION RATE OF APPROXIMATELY 158 PERCENT​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ",
    "published": "2018-03-02T15:38:00.000+02:00",
    "crawled": "2018-03-03T17:22:58.005+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "reuters",
        "expres2ion",
        "biotech",
        "holding",
        "ab",
        "press",
        "release",
        "expres2ion",
        "right",
        "issue",
        "oversubscribed",
        "issue",
        "approximately",
        "sek",
        "million",
        "issue",
        "subscribed",
        "approximately",
        "sek",
        "million",
        "issue",
        "subscribed",
        "approximately",
        "sek",
        "million",
        "corresponding",
        "subscription",
        "rate",
        "approximately",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}